CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
14.26
0.92%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.25
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

XOMA Corp ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 14.06
Open* 13.98
1-Year Change* -21.64%
Day's Range* 13.69 - 14.19
52 wk Range 13.68-26.00
Average Volume (10 days) 18.13K
Average Volume (3 months) 878.97K
Market Cap 171.17M
P/E Ratio -100.00K
Shares Outstanding 11.47M
Revenue 4.03M
EPS -2.69
Dividend (Yield %) N/A
Beta 0.85
Next Earnings Date Nov 1, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 29, 2023 14.06 -0.10 -0.71% 14.16 14.42 13.80
Sep 28, 2023 14.21 -0.13 -0.91% 14.34 14.66 14.16
Sep 27, 2023 14.42 0.43 3.07% 13.99 14.61 13.77
Sep 26, 2023 14.20 -0.09 -0.63% 14.29 14.72 13.97
Sep 25, 2023 14.66 0.18 1.24% 14.48 14.75 14.47
Sep 22, 2023 15.46 0.09 0.59% 15.37 15.72 15.24
Sep 21, 2023 15.70 0.01 0.06% 15.69 16.17 15.39
Sep 20, 2023 15.69 -0.28 -1.75% 15.97 16.19 15.34
Sep 19, 2023 15.97 0.10 0.63% 15.87 16.42 15.87
Sep 18, 2023 16.23 -0.76 -4.47% 16.99 17.18 16.20
Sep 15, 2023 17.18 1.49 9.50% 15.69 17.43 15.59
Sep 14, 2023 15.98 0.51 3.30% 15.47 16.12 15.47
Sep 13, 2023 15.68 0.88 5.95% 14.80 15.90 14.80
Sep 12, 2023 15.42 0.10 0.65% 15.32 15.57 14.81
Sep 11, 2023 15.59 0.47 3.11% 15.12 15.59 14.48
Sep 8, 2023 15.17 0.55 3.76% 14.62 15.17 14.62
Sep 7, 2023 14.88 0.66 4.64% 14.22 15.05 14.02
Sep 6, 2023 14.72 0.55 3.88% 14.17 14.72 13.88
Sep 5, 2023 14.46 0.48 3.43% 13.98 14.68 13.97
Sep 1, 2023 14.23 0.26 1.86% 13.97 14.23 13.57

XOMA Corporation Events

Time (UTC) Country Event
Wednesday, November 1, 2023

Time (UTC)

12:30

Country

US

Event

Q3 2023 XOMA Corp Earnings Release
Q3 2023 XOMA Corp Earnings Release

Forecast

-

Previous

-
Thursday, March 7, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 XOMA Corp Earnings Release
Q4 2023 XOMA Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 6.027 38.16 29.385 18.37 5.299
Revenue 6.027 38.16 29.385 18.37 5.299
Total Operating Expense 23.441 20.931 16.969 22.255 22.156
Selling/General/Admin. Expenses, Total 23.191 20.46 16.799 21.002 18.563
Research & Development 0.153 0.171 0.17 1.253 1.682
Unusual Expense (Income) 0 0.3 1.911
Operating Income -17.414 17.229 12.416 -3.885 -16.857
Interest Income (Expense), Net Non-Operating 0.255 -1.345 -0.832 -1.63 -1.465
Other, Net 0.04 0.005 0.213 3.533 4.881
Net Income Before Taxes -17.119 15.889 11.797 -1.982 -13.441
Net Income After Taxes -17.104 15.798 13.298 -1.982 -13.343
Net Income Before Extra. Items -17.104 15.798 13.298 -1.982 -13.343
Net Income -17.104 15.798 13.298 -1.982 -13.343
Income Available to Common Excl. Extra. Items -22.576 7.968 9.01 -1.982 -13.343
Income Available to Common Incl. Extra. Items -22.576 7.968 9.01 -1.982 -13.343
Diluted Net Income -22.576 7.968 9.01 -1.982 -13.343
Diluted Weighted Average Shares 11.413 12.192 11.503 8.763 8.373
Diluted EPS Excluding Extraordinary Items -1.9781 0.65354 0.78327 -0.22618 -1.59357
Diluted Normalized EPS -1.9781 0.67801 0.78327 -0.22618 -1.44522
Total Adjustments to Net Income -5.472 -7.83 -4.288 0
Dilution Adjustment 0
Depreciation / Amortization 0.097
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 1.658 0.437 1.486 0.451 0.983
Revenue 1.658 0.437 1.486 0.451 0.983
Total Operating Expense 7.615 10.607 7.696 4.823 5.75
Selling/General/Admin. Expenses, Total 5.777 6.196 7.571 4.794 5.71
Research & Development 0.039 0.054 0.028 0.029 0.04
Operating Income -5.957 -10.17 -6.21 -4.372 -4.767
Interest Income (Expense), Net Non-Operating 0.557 0.357 0.214 0.194 0.058
Other, Net 0 0 0.005 0 0.039
Net Income Before Taxes -5.4 -9.813 -5.991 -4.178 -4.67
Net Income After Taxes -5.4 -9.813 -5.976 -4.178 -4.67
Net Income Before Extra. Items -5.4 -9.813 -5.976 -4.178 -4.67
Net Income -5.4 -9.813 -5.976 -4.178 -4.67
Total Adjustments to Net Income -1.368 -1.368 -1.368 -1.368 -1.368
Income Available to Common Excl. Extra. Items -6.768 -11.181 -7.344 -5.546 -6.038
Income Available to Common Incl. Extra. Items -6.768 -11.181 -7.344 -5.546 -6.038
Diluted Net Income -6.768 -11.181 -7.344 -5.546 -6.038
Diluted Weighted Average Shares 11.466 11.46 11.452 11.447 11.421
Diluted EPS Excluding Extraordinary Items -0.59027 -0.97565 -0.64129 -0.48449 -0.52868
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.4529 -0.97565 -0.64129 -0.48449 -0.52868
Unusual Expense (Income) 1.575 0 0 0
Depreciation / Amortization 0.224 0.225 0.097
Other Operating Expenses, Total 0 4.132
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 61.253 96.973 88.065 59.973 47.626
Cash and Short Term Investments 58.161 94.102 84.222 56.688 45.78
Cash & Equivalents 56.688 45.78
Short Term Investments 0.335 0.774
Total Receivables, Net 2.367 0.209 1.789 2.933 1.468
Accounts Receivable - Trade, Net 0.001 0.209 0.263 2.933 1.468
Prepaid Expenses 0.725 0.613 0.443 0.352 0.378
Total Assets 140.382 166.562 125.285 95.724 63.785
Property/Plant/Equipment, Total - Net 0.036 0.213 0.38 0.544 0.059
Property/Plant/Equipment, Total - Gross 0.129
Accumulated Depreciation, Total -0.07
Other Long Term Assets, Total 0.26 0.301 0.572 0.151 15.708
Total Current Liabilities 6.818 12.967 12.302 8.875 5.703
Accounts Payable 0.524 1.072 0.456 0.614 1.244
Accrued Expenses 2.952 0.72 0.821 1.108 2.298
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 8.088 5.184 0.789
Other Current Liabilities, Total 3.342 11.175 2.937 1.969 1.372
Total Liabilities 16.368 24.686 38.861 51.736 45
Total Long Term Debt 0 0 12.764 27.093 21.69
Long Term Debt 0 12.764 27.093 21.69
Other Liabilities, Total 9.55 11.719 13.795 15.768 17.607
Total Equity 124.014 141.876 86.424 43.988 18.785
Common Stock 0.086 0.085 0.084 0.073 0.065
Additional Paid-In Capital 1306.27 1307.03 1267.38 1238.3 1211.12
Retained Earnings (Accumulated Deficit) -1182.39 -1165.29 -1181.09 -1194.38 -1192.4
Total Liabilities & Shareholders’ Equity 140.382 166.562 125.285 95.724 63.785
Total Common Shares Outstanding 11.454 11.3153 11.2288 9.75858 8.69072
Long Term Investments 0 1.693 0.681 0.392
Note Receivable - Long Term 63.683 69.075 34.575 34.375
Cash 57.826 93.328 84.222
Other Current Assets, Total 0 2.049 1.611
Redeemable Preferred Stock 0.049 0.049 0.049
Total Preferred Shares Outstanding 0.9856 0.984 0.984
Intangibles, Net 15.15
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 45.073 79.741 87.261 89.614
Cash and Short Term Investments 44.611 78.728 83.705 88.343
Cash 44.3 78.285 83.182 87.796
Total Receivables, Net 0.006 0.016 2.505 0.025
Accounts Receivable - Trade, Net 0.006 0.016 0.005 0.025
Prepaid Expenses 0.456 0.997 1.051 0.409
Other Current Assets, Total 0 0 0.837
Total Assets 133.664 146.131 154.222 159.16
Property/Plant/Equipment, Total - Net 0.073 0.081 0.126 0.17
Long Term Investments
Note Receivable - Long Term 73.333 66.049 66.575 69.075
Other Long Term Assets, Total 0.26 0.26 0.26 0.301
Total Current Liabilities 10.094 5.425 8.424 7.89
Accounts Payable 0.437 0.985 1.153 0.787
Accrued Expenses 6.196 1.293 1.159 1.037
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 3.461 3.147 6.112 6.066
Total Liabilities 19.138 15.806 19.266 19.236
Total Long Term Debt 0 0 0 0
Long Term Debt
Other Liabilities, Total 9.044 10.381 10.842 11.346
Total Equity 114.526 130.325 134.956 139.924
Redeemable Preferred Stock 0.049 0.049 0.049 0.049
Common Stock 0.086 0.086 0.086 0.086
Additional Paid-In Capital 1306.6 1306.61 1307.06 1307.36
Retained Earnings (Accumulated Deficit) -1192.2 -1176.42 -1172.24 -1167.57
Total Liabilities & Shareholders’ Equity 133.664 146.131 154.222 159.16
Total Common Shares Outstanding 11.461 11.4508 11.4238 11.4099
Total Preferred Shares Outstanding 0.9856 0.984 0.984 0.984
Short Term Investments 0.311 0.443 0.523 0.547
Intangibles, Net 14.925
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -17.104 15.798 13.298 -1.982 -13.343
Cash From Operating Activities -12.879 22.678 10.092 -0.285 -12.644
Cash From Operating Activities 0.007 0.007 0.022 0.025 0.03
Non-Cash Items 4.302 7.759 -3.415 5.767 3.651
Cash Interest Paid 0 0.311 0.692 0.558 0.081
Changes in Working Capital -0.181 -0.886 0.187 -4.095 -2.982
Cash From Investing Activities -20.221 -26.5 -0.209 -19.3 -15.006
Capital Expenditures -15.247 0 -0.009 0 -0.006
Other Investing Cash Flow Items, Total -4.974 -26.5 -0.2 -19.3 -15
Cash From Financing Activities -4.451 12.835 19.793 30.493 29.939
Issuance (Retirement) of Stock, Net 2.419 41.584 29.45 22.539 22.915
Issuance (Retirement) of Debt, Net 0 -21.377 -5.33 8.547 7.487
Foreign Exchange Effects 0 0.02
Net Change in Cash -37.551 9.013 29.676 10.908 2.309
Financing Cash Flow Items -1.398 -3.873 -4.327 -0.593 -0.463
Cash Taxes Paid 0.076 0 1.637
Total Cash Dividends Paid -5.472 -3.499
Amortization 0.097
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -9.813 -17.104 -11.128 -6.95 -2.28
Cash From Operating Activities -4.924 -12.879 -8.989 -5.326 -1.009
Cash From Operating Activities 0.001 0.007 0.007 0.003 0.002
Non-Cash Items 1.764 4.302 3.162 2.235 1.332
Cash Interest Paid 0 0 0 0 0.095
Changes in Working Capital 2.899 -0.181 -1.03 -0.614 -0.063
Cash From Investing Activities -7.234 -20.221 -4.974 -5 -5
Other Investing Cash Flow Items, Total -7.234 -4.974 -4.974 -5 -5
Cash From Financing Activities -1.368 -4.451 -3.129 -1.869 -0.735
Financing Cash Flow Items 0 -1.398 -1.398 -1.038 -0.973
Issuance (Retirement) of Stock, Net 0 2.419 2.373 1.905 1.606
Issuance (Retirement) of Debt, Net 0 0 0 0
Net Change in Cash -13.526 -37.551 -17.092 -12.195 -6.744
Total Cash Dividends Paid -1.368 -5.472 -4.104 -2.736 -1.368
Capital Expenditures -15.247
Cash Taxes Paid 0.076 0.095 0.095
Amortization 0.225 0.097

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

XOMA Corporation Company profile

About XOMA Corp

XOMA Corporation (XOMA) is a biotechnology royalty aggregator. The Company's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The Company's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The Company's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, XOMA Corp revenues increased 30% to $38.2M. Net income applicable to common stockholders decreased 12% to $8M. Revenues reflect Europe segment increase of 40% to $35M, United States segment increase from $1.3M to $2.6M. Net income was offset by Stock-based Compensation in SGA increase of 56% to $6.2M (expense).

Equity composition

Common Stock $.0075 Par, 03/11, 46,666,666 auth., 29,510,963 issd. Insiders own 7.83%. PO: 4/91, 3.4M shs @ $26.50 by Alex. Brown& Sons. PO 6/01, 3M shs @ $15 by U.S. Bancorp Piper Jaffray. Series B Prfd. Stock $.05 Par, 8K auth., 2,959 issd. *1996, Co.'s 4% Conv. Subd. Debentures were conv. into 2M shs. of Common. 08/10, 1-for-15 reverse split.

Industry: Bio Therapeutic Drugs

Suite 310
2200 Powell Street
EMERYVILLE
CALIFORNIA 94608
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

Oil - Crude

87.89 Price
-2.090% 1D Chg, %
Long position overnight fee 0.0584%
Short position overnight fee -0.0803%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.53 Price
+0.830% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Gold

1,831.14 Price
-0.890% 1D Chg, %
Long position overnight fee -0.0195%
Short position overnight fee 0.0113%
Overnight fee time 21:00 (UTC)
Spread 0.30

BTC/USD

28,021.75 Price
+3.330% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading